Allorion Therapeutics Co. Ltd. has patented nonreceptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of psoriasis, inflammatory bowel disease, psoriatic arthritis, ulcerative colitis, Crohn's disease and systemic lupus erythematosus.
Sironax Ltd. has patented receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors reported to be useful for the treatment of ulcerative colitis, Crohn's disease, psoriasis, rheumatoid arthritis, amyotrophic lateral sclerosis, Alzheimer's disease and viral infections.
Shire Human Genetic Therapies Inc. has discovered new plasma kallikrein (KLKB1) inhibitors reported to be useful for the treatment of hereditary angioedema and diabetic macular edema.
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have synthesized orexin OX2 receptor antagonists reported to be useful for the treatment of major depression and insomnia.
Idorsia Pharmaceuticals Ltd. has described cystic fibrosis transmembrane conductance regulator (CFTR) modulators reported to be useful for the treatment of cystic fibrosis.
Maze Therapeutics has presented glycogen [starch] synthase, muscle (GYS1) inhibitors reported to be useful for the treatment of cancer and Pompe disease.
Vincere Biosciences Inc. has presented new ubiquitin carboxyl-terminal hydrolase 30 (USP30) inhibitors reported to be useful for the treatment of cancer, cardiovascular disorders, eye disorders, renal disorders, peroxisomal disorders, ataxia, pulmonary fibrosis and neurodegeneration.
The University of Arizona has divulged nonstructural protein 3 (Nsp3; PL-PRO) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection.
RSS